VASTRA FROLUNDA, Sweden--(BUSINESS WIRE)--Regulatory News: The biomaterials company Artimplant (STO:ARTIB) has granted the American company Biomet Sports Medicine the global, non-exclusive right to market Artelon® Tissue Reinforcement for a further four indications. At the same time, the previously exclusive rotator cuff agreement has been made non-exclusive. In September, the implant’s FDA clearance for reinforcement of the shoulder rotator cuff was extended to also include tendons in, and linked to, the knee, upper arm, front thigh muscle and heel. Following renegotiation of the previously exclusive agreement, Artimplant now has the opportunity, alongside Biomet, to exploit Artelon® Tissue Reinforcement for all cleared areas of use worldwide. Biomet also receives the right to sell a product specifically designed for Achilles rupture, which is the largest market after rotator cuff repair.
